Skip to main content
SpringerLink
Log in

Prostate cancer old problems and new approaches

Part III. Prevention and treatment

  • Seminar
  • Published:
Pathology & Oncology Research

Abstract

In Part Three of this review, we begin with an analysis of prevention strategies for prostate cancer followed by a discussion of the clinical use of molecular techniques for the evaluation and treatment of patients with clinically localized prostate cancer. New developments in neutron and photon therapy of prostate cancer are addressed as well as the use of systemic radiotherapy for the treatment of bone métastases. Finally, we conclude with the role of hormonal therapy in the treatment of prostate cancer and the current status of development of chemo therapeutic regimens for the treatment of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boone C, Delloff G, Malone W: Identification of candidate cancer chemoprevention agents and their evaluation on animal models and human critical trials: A review. Cancer Res 50:2–9, 1990.

    PubMed  CAS  Google Scholar 

  2. Schall RP, Sekar J, Tandom PM, Susskind BM: Difluoromethylornithine (DMFO) arrests murine CTL development in the late, pre-effector stage. Immunopharmacology 21:129–143, 1991.

    Article  PubMed  CAS  Google Scholar 

  3. Kadmon D: Chemoprevention in prostate cancer the role of difluromethylornithine (DMFO). J Cell Biochem [Suppl] 16H: 122–127, 1992.

    Article  Google Scholar 

  4. Mickey DD, Carvalho F, Foulkes K: Conventioal chemothera-peutic agents combined with DMSO or DFMO in treatment of rate prostate carcinoma. Prostate 15:221–232. 1989.

    Article  PubMed  CAS  Google Scholar 

  5. Love RR, Carbone PP, Vennan AK, et al: Randomized phase I Chemoprevention dose-seeking study of alpha-difluoromehty-lornithine. J Natl Cancer Inst 85:732–737. 1993.

    Article  PubMed  CAS  Google Scholar 

  6. Meyskens FL, Kingsley EM, Galttke T, et al: A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Invest New Drugs 4:257–262, 1986.

    Article  PubMed  CAS  Google Scholar 

  7. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endercrinology 122:552–562, 1988b.

    CAS  Google Scholar 

  8. Brawley OW, Ford L, Thompson I, et al: 5-alpha-reductase inhibitors and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 3:1–6, 1994.

    Google Scholar 

  9. Imperati-McGinley J, Guerrero L, Gautier T, Peterson RE: Steroid 5a-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186:1213–1215. 1974.

    Article  Google Scholar 

  10. Walsh PC, Madden JD, Harrod MJ, et al: Familial incompete male pseudohermaphroditism. type 2: decreased dihydrotes-tosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 291:944–949, 1974.

    PubMed  CAS  Google Scholar 

  11. Gormley GJ: Role of 5-alpha-reductase inhibitors in the treatment of advanced proslalic carcinoma. Urol Clin North Am 18:93–98, 1991.

    PubMed  CAS  Google Scholar 

  12. Fakih, M, Yagoda, A, Replace T, et al: Inhibition of prostate cancer growth by estramustine and colchicine. Prostate 26:310–315. 1995.

    Article  PubMed  CAS  Google Scholar 

  13. Pienta KJ, Redman DO, Hussion M, et al: Inhibition of prostate cancer growth by estramustine and etoposide. Cancer 75:1920–1926, 1995a.

    Article  Google Scholar 

  14. Pienta KJ, Replogle T, Lehr JE: Inhibition of prostate cancer growth by vinblastine and tamoxifen. Prostate 26:270–274. 1995b.

    Article  PubMed  CAS  Google Scholar 

  15. Nguyen N, Lehr JE, Pienta KJ: Pentosan inhibits angiogenesis in vitro and suppress prostate tumor growth in vivo. Anticancer Res. 13:2143–2148, 1993

    PubMed  CAS  Google Scholar 

  16. Pienta KJ, Naik H, Akhtar A et al: Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87:348–353, 1995c.

    Article  PubMed  CAS  Google Scholar 

  17. Lerner SP, Seale-Hawkins C, Carlton CE, Jr., Scardino PT: The Risk of Dying of Prostate Cancer in Patients with Clincally Localized Disease. J Urol 146(4): 1040–1045, 1991.

    PubMed  CAS  Google Scholar 

  18. McCollough DL: Diagnosis and Staging of Prostate Cancer. In: Diagnosis and Management of Genitourinary Cancer, Skinner DG, Lieskovsky G. eds. W.B. Saundcrs. Philadelphia.PA. Diagnosis and Management of Genitourinary Cancer. 405–416, 1988.

    Google Scholar 

  19. Partin AW, Yoo J, Carter HB, et al: The Use of Prostatic Specific Antigen, Clinical Stage and Gleason Score to Predict PAtho-logical Stage in Men with Localized Prostate Cancer. J Urol 150:110–114. 1993.

    PubMed  CAS  Google Scholar 

  20. Epstein JI, Pizov G, Walsh PC: Correlation of Pathologic Findings with Progression after Radical Retropubic Prostatectomy. Cancer 71:3582–3593. 1993b.

    Article  PubMed  CAS  Google Scholar 

  21. Spires SE, Cibull ML, Wood DP, Jr., et al: Gleason Histologie Grading in Prostatic Carcinoma. Arch Pathol Lab Med 118:705–708, 1994.

    PubMed  CAS  Google Scholar 

  22. Wood DP Jr., Banks FR, Humphreys S, Rangnekar VM: Sensitivity of immuno-histochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem 42:505–511, 1994b.

    PubMed  CAS  Google Scholar 

  23. Wood DP Jr., Banks ER, Humphreys S, et al: Identification of Bone Marrow Micrometastases in Patients with Prostate Cancer. Cancer 74:2533–2540, 1994a.

    Article  PubMed  Google Scholar 

  24. Kallioniemi A, Kallioniemi OP, Sudar D, et al: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818–821, 1992.

    Article  PubMed  CAS  Google Scholar 

  25. Cher MF, MacGrogan D, Bookslein R, et al: Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 11:153–162, 1994.

    Article  PubMed  CAS  Google Scholar 

  26. Cher ML, Chew K, Rosenau W, Carroll PR: Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 26:87–93, 1995a.

    Article  PubMed  CAS  Google Scholar 

  27. Laramore GE, Krall GF, Thomas FJ, et al: Fast neutron radiotherapy for locally advanced prostate cancer: Results of an RTOG randomized study. Int J Rad One Biol Phys 11:1621–1627, 1985.

    CAS  Google Scholar 

  28. Russell KJ, Caplan RJ, Faramore GF, et al: Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int J Rad One Biol Phys 28:47–54, 1993.

    Google Scholar 

  29. Austin-Seymour M, Caplan RC, Rusell K, et al: Impact of a multileal collimator on treatment morbidity in localized carcinoma of the prostate. Prostate Cancer. Int J Rad One Biol Phys 30:1065–1072, 1994.

    CAS  Google Scholar 

  30. Sharma R, Wonnelink C, Yudelev M. RF, et al: Description of a 3D conformai neutron and photon radiotherapy technique for prostate cancer, in press.

  31. Maughan RF, Yudelev: Physical characteristics of a d(48.5)+Be neutron beam produced by superconducting cyclotron. Med Phys, in press.

  32. Maughan RL, Powers WE, Blosser HG: A superconducting cyclotron for fast neutron radiation therapy. Med Phys 21:779–785, 1994.

    Article  PubMed  CAS  Google Scholar 

  33. Maughan RL, Yudelev M, Forman JD, et al: A unique superconducting cyclotron for neutron radiation therapy. Front Med Phys, in press.

  34. Forman JD, Wannelink C, Sharma R, et al: Description and evaluation of 3-Dimensional conformai neutron and photon radiotherapy for locally advanced adenocarcinoma of the prostate. Am J Clin One. in press.

  35. Lawton CA, Won M, Pilepich MV, et al: Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate-analysis of RTOG Study 7506 and Study 7706. Int J Rad One Biol Phys 21:935–939, 1991.

    CAS  Google Scholar 

  36. Kaplan EL, Meier P: Nonparametrie estimation from incomplete observations. J Am Stat Assoe 53:457–481, 1958.

    Article  Google Scholar 

  37. Mehla C, Patel N: StatXaet user manual. Cambridge MA: CYTEL Software Corporation, 1992.

    Google Scholar 

  38. Zeitman AL, Shipley WU, Coen JJ: Prostate: new insights into outcome from repeat biopsy and prastate specific antigen follow-up. J Urol 5:1806–1815, 1993.

    Google Scholar 

  39. Widmark A, Fransson P, Tavelin B: Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population.

  40. Forman JD, Duclos M, Shamsa F, et al: Conformai neutronphoton irradiation for localized prostate cancer. Radiotherapy and Oncology, submitted.

  41. Oxford Textbook of Palliative Medicine (Eds: Doyle D, Hanks GWC, and MacDonald N). Oxford University Press, 1993.

  42. Scardino PT, Weaver R, Hudson MA: Early detection of prostate cancer. Hum Pathol 23:211–222, 1992.

    Article  PubMed  CAS  Google Scholar 

  43. Pistenma DA, Bagshaw MA, Feiha FS: Extended field radiation therapy for prostatic adenocarcinoma: Status report of a limited prospective trial. In Cancer of the Genitourinary Tract. (Eds: Johnson DE. Samuels ML). New York. Raven Press, 1979.

    Google Scholar 

  44. Prout GR, Heaney JA, Griffin P, et al: Nodal involvement as a prognostic indicator in patients with prostatic carcinoma. J Urol 124:226. 1980.

    PubMed  Google Scholar 

  45. Batson OV: The role of the vertebral veins in metastatic processes. Ann Int Med 16:38. 1942.

    Google Scholar 

  46. Dodds PR, Caride VJ, Lytton B: The role of vertebral veins in the dissemination of prostatic carcinoma. J Urol 126:753, 1981.

    PubMed  CAS  Google Scholar 

  47. Gilbert HA, Dagan AR: Métastases: Incidence, Detection, and Evaluation. In Fundamental Aspects of Métastases. (Ed: Weiss L) Amsterdam, North Holland. Elsevier Excerpta Medica, 1976.

    Google Scholar 

  48. Pagani JJ, Libshitz HI: Imaging in bone métastases. Rad Clinics of NA 20:545–560, 1982.

    CAS  Google Scholar 

  49. Glasko CSB. Skeletal métastases. Clin Orthop 210:18–30. 1986.

    Google Scholar 

  50. Wilner D: Cancer Metastasis to Bone. In Radiology of Bone Tumors and Allied Disorders. (Ed: Wilner D) Philadelphia: WB Saunders. 3641–3908, 1982.

    Google Scholar 

  51. Tong D, Gilliek L, Hendrickson FR: The palliation of symptomatic osseous metastases: Final results of the Radiation Therapy Oncology Group. Cancer 50:893–899, 1982.

    Article  PubMed  CAS  Google Scholar 

  52. Blitzner PH: Reanalysis of the RTOG study of the palliation of symptomatic osseous mtastases. Cancer 55:1468–1472, 1985.

    Article  Google Scholar 

  53. Cole DJ: A randomised trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin Oncol 1:59–62, 1989.

    Article  CAS  Google Scholar 

  54. Price P, Hoskin PJ, Easton D, et al: Low dose single fraction radiotherapy in the treatment of metastatic bone pain: A pilot study. Radiother Oncol 12:297–300, 1988.

    Article  PubMed  CAS  Google Scholar 

  55. Lane JM, Sculo TP, Zolan S: Treatment of pathologic fractures of the hip by endoprosthetic replacement. J Bone Joint Surg 62:954–959, 1980.

    PubMed  CAS  Google Scholar 

  56. Bruckman JF, Bloomer WD: Management of spinal cord compression. Semin Oncol 5:135–140. 1978.

    PubMed  CAS  Google Scholar 

  57. Black P: Spinal metastases: Current status and recommended guidelines for management. Neurosurgery 5:726–746, 1979.

    Article  PubMed  Google Scholar 

  58. Gilbert RW, Kim JH, Posner JB: Epidural spinal cord compression from metastatic tumor: Diagnosis and treatment. Ann Neurol 3:40–51, 1978.

    Article  PubMed  CAS  Google Scholar 

  59. Rodichok RD, Ruckdeschel JC, Harper GR, et al: Early detection and treatment of spinal epidural metastases: The role of myelography. Ann Neurol 20:696–702, 1986.

    Article  PubMed  CAS  Google Scholar 

  60. Portenoy RK, Galer BS. Salamon O, et al: Identification of epidural neoplasm: radiography and bone ccintigraphy in the symptomatic and asymptomatic spine. Cancer 64:2207–2213, 1989.

    Article  PubMed  CAS  Google Scholar 

  61. Cannody RF, Yang PJ, Seely GW et al: Spinal cord compression due to metastatic disease: Diagnosis with MR imaging versus myelography. Radiology 173:225–229, 1989.

    Google Scholar 

  62. Li KC, Poon PY: Sensitivity and specificity of MRI in detecting malignant spinal cord compression and in distinguishing malignant from benign compression fractures of vertebrae. MRI 6:547–556, 1988.

    Article  CAS  Google Scholar 

  63. Sze G, Krol G, Zimmerman RD: Malignant extradural spinal tumors: MR imaging with Gd-DTPA. Radiology 167:217–223, 1988.

    PubMed  CAS  Google Scholar 

  64. Friedman M, Kim TM, Panahon AM: Spinal cord compression in malignant lymphoma. Cancer 37:1485, 1976.

    Article  PubMed  CAS  Google Scholar 

  65. Dessauer F: Eine neue Anordung mur Roentgen bestrahlung. Archiven fur Physiche Medezin und Technologie (Leipzig) 2:218–223, 1905.

    Google Scholar 

  66. Fitzpatrick PJ, Rider WD: Halfbody radiotherapy. Int J Rad Oncol Biol Phys 1:197, 1976.

    CAS  Google Scholar 

  67. Epstein LM, Stewart BH, Antung AR, et al: Half and total body irradiation for carcinoma of the prostate. J Urol 12:30. 1979.

    Google Scholar 

  68. Salazar OM, Rubin P, Keller B, et al: Systemic (half-body) radiation therapy: response and toxicity. Int J Rad Oncol Biol Phys 4:937–950, 1978.

    CAS  Google Scholar 

  69. Salazar OM, Rubin P, Hendrickson FR, et al: Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group Report. Cancer 58:29–36. 1986.

    Article  PubMed  CAS  Google Scholar 

  70. Jacobsson H and Naslund I: Reduced incidence of bone metastases in irradiated areas after external radiation therapy of prostatic carcinoma. Int J Rad Oncol Biol Phys 20:1297–1303, 1991.

    CAS  Google Scholar 

  71. Kaplan ID, Valdayni R, Cox RS: Reduction of spinal metastases after preemptive irradiation in prostate cancer. Int J Rad Oncol Biol Phys 18:1019, 1990.

    CAS  Google Scholar 

  72. Poulter CA, Cosmatos D, Rubin P, et al: A report of RTOG 82-06: A Phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Rad Oncol Biol Phys 23:207, 1992.

    CAS  Google Scholar 

  73. Rubin P, Scarantino CW: Hemibody Irradiation. In: Mauch PM and Loeffler JS, eds. Radiation Oncology: Technology and Biology. Philadelphia: W. B. Saunders Company: 1994.

    Google Scholar 

  74. Scaraniino CW, Ornitz RD, Hoffman LG, et al: On the mechanism of radiation-induced emesis (RIE): the role of serotonin. Int J Rad Oncol Biol Phys 30:825–830, 1994.

    Google Scholar 

  75. Pecher C: Biological investigations with radioactive calcium and strontium: Preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer. University of California Publications Pharmacol 11:117–149, 1942.

    Google Scholar 

  76. Laing AH, Ackery DM, Bayly RJ, et al: Strontium-89 chloride for pain palliation in prostate skeletal malignancy. Br J Radiol 64:816–822. 1991.

    Article  PubMed  CAS  Google Scholar 

  77. Tenvall J, Darte L, Lundyren R et al: Palliation of multiple bone metastases from prostate carcinoma with strontium-89. Acta Oncol 27:365–369. 1988. Vol 2. No 4. 1996

    Article  Google Scholar 

  78. Porter AT, McEwan AJB, Powe JE, et al: Results of a randomized Phase III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in management of endocrine resistant metastatie prostate cancer. Int J Rad Oncol Biol Phys 25:805–813, 1993.

    CAS  Google Scholar 

  79. Quilty PM, Kirk D, Bolder JJ, et al: A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatie prostate cancer. Radiotherapy and Oncology 31:33–40, 1994.

    Article  PubMed  CAS  Google Scholar 

  80. Porter AT, Davis LP: Systemic radtonucleide therapy ot bone metastases with strontium-89. Oncology 8:93–96, 1994.

    PubMed  CAS  Google Scholar 

  81. Huggins C, Hodges CV: Studies on Prostatic Cancer: The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphalases in Metastatie Carcinoma of the Prostate. Cancer Res 1:293–297, 1941.

    CAS  Google Scholar 

  82. Stamey TA, McNeal JE: Adenocarcinoma of the Prostate. In Walsh PC, Retik AB. Stamey TA, Vaughan ED. Jr. (eds): “Campbell’s Urology.” Philadelphia. Pennsylvania: W. B. Saunders Company, 1159–1221, 1992.

    Google Scholar 

  83. Byar DP: Proceedings: The Veterans Administration Cooperation Urological Research Group’s Studies of Cancer of the Prostate. Cancer 32:1126–1130, 1973.

    Article  PubMed  CAS  Google Scholar 

  84. Crawford ED, Eisenberger MA, McEeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A Controlled Trial of Leuprolide with and Without Flutamide in Prostatic Carcinoma. N Engl J Med 321:419–424, 1989.

    PubMed  CAS  Google Scholar 

  85. Janknegt RA: Total Androgen Blockade with the Use of Orchiectomy and Nilutamide (Anandron) or Placebo as Treatment of Metastatie Prostate Cancer: Anadron International Study Group. Cancer(12 Suppl) 72:3874–3877, 1993.

    Article  PubMed  CAS  Google Scholar 

  86. Labrie F, Dupont A, Belanger A: Complete androgen blockade for the treatment of prostate cancer. In De Vita VT. Jr.. Hellman S. Rosenberg SA: (eds): “Important Advances in Oncology.” Philadelphia: J.B. Lippincott Co., 193–217, 1985.

    Google Scholar 

  87. Gaddipati JP, McEeod DG, Heidenberg HB, et al: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54:2861–2864, 1994.

    PubMed  CAS  Google Scholar 

  88. Schoenberg MP, Hakimi JM, Wang S, et al: Microsatellite Mutation (CAG24-l 8) in the Androgen Receptor Gene in Human Prostate Cancer. Biochem Biophys Res Commun 198:74–80, 1994.

    Article  PubMed  CAS  Google Scholar 

  89. Sartor O, Cooper M, Weinberger M, et al: Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of “Hormone-Refractory” Prostate Cancer. J Natl Cancer Inst 86(3):222–227, 1994.

    Article  PubMed  CAS  Google Scholar 

  90. Akakura K, Bruchovsky N, Goldenberg SL, et al: Effects of Intermittent Androgen Suppression on Androgen-Dependent Tumors. Cancer 71:2782–2790, 1993.

    Article  PubMed  CAS  Google Scholar 

  91. Klotz LH, Herr H, Morse MJ, Whitmore WF: Intermittent Endocrine Therapy for Advanced Prostate Cancer. Cancer 58:2546–2550, 1986.

    Article  PubMed  CAS  Google Scholar 

  92. Eisenberger MA, Crawford ED, Mcleod D, et al: The prognostic significance of prostate specific antigen in stage D2 prostate cancer. Interim evaluation of intertrroup study 0105 Proc Am Soc Clin Oncol. 14:235, #613, 1995a.

    Google Scholar 

  93. Hussain M, Wolf M, Marshall E, et al: Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone refractory prostate cancer: A Southwest Oncology Group study. J Clin Oncol 12:1868–1875, 1994b.

    PubMed  CAS  Google Scholar 

  94. Myers C, Cooper M, Stein C, et al: Suramin A novel growth factor antagonist with activity in hormone refractory metastatie prostate cancer. J Clin Oncol 10:881–889, 1992.

    PubMed  CAS  Google Scholar 

  95. Kobayashi K, Yokes EE, Vogelzang NJ, et al: Phase 1 study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196–2207,1995.

    PubMed  CAS  Google Scholar 

  96. Eisenberger MA, Sinibaldi VJ, Rexno LM, et al: Phase 1 and clinical evaluation of pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13:2174–2186, 1995b.

    PubMed  CAS  Google Scholar 

  97. Pctrylak DP, Yagoda A, O’Conner J, et al: Phase II trial of suramin in hormone refractory prostate cancer. Proc ASCO 13:249, 1994.

    Google Scholar 

  98. Kelly K, Cuiiey T, Leibertz C, et al: Prospective evaluation of hydrocortisone and suramin in patients with androgen independent prostate cancer. J Clin Oncol 13:2208–2213, 1995.

    PubMed  CAS  Google Scholar 

  99. Amato R, Logothetis C, Dexeus F: Preliminary results of a phase II trial of estramustine and vinblastine for patients with progressive hormone refractory prostate cancer. Proc AACR 32:186, 1991.

    Google Scholar 

  100. Hudes GR, Greenberg R, Kriger RL, et al: Phase II study of estramusline and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J Clin Oncol 10:1754–1761, 1992.

    PubMed  CAS  Google Scholar 

  101. Scidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostatic specific antigen as a clinical trial endpoint for hormone refractory prostate cancer. J Urol 147:931–934 1992.

    Google Scholar 

  102. Hussain M, Pienta KJ, Redman BG, et al: Oral etoposide in the treatment of hormone refractory prostate cancer. Cancer 74:100–103,1994a.

    Article  PubMed  CAS  Google Scholar 

  103. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005–2012, 1994.

    PubMed  CAS  Google Scholar 

  104. Roth B, Yeap B, Wilding G, et al: Taxol in advanced hormone refractory prostate cancer: An ECOG phase II trial. Proc Am Soc Clin Oncol 11:196, #598, 1992.

    Google Scholar 

  105. Polin L, Jones J, Demchik L, et al: Treatment ol human prostate tumor LNCaP with standard and investigational agents in SCID mice. Prostate. In press, 1996.

  106. Hudes G, Nathan E, Chapman A, et al: Combined antimicrotubule therapy of metastatie prostate cancer with 96-hr paelitaxel and estramusline: Activity in hormone refractory disease. Proc Am Soc Clin Oncol 14:237, #622, 1995.

    Google Scholar 

  107. Moore MJ, Osoba D, Murphy K, et al: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689–694, 1994.

    PubMed  CAS  Google Scholar 

  108. Tannock I, Osoba D, Ernst S, et al: Chemotherapy with mitoxantrone and prednisone pallites patients with hormone resistant prostate cancer. Results of a randomized Canadian trial. Proc Am Soc Clin Oncol 14:245, 1995.

    Google Scholar 

  109. Kelly WMK, Scher HI, Mazumdar M, et al: Prostate specific antigen as a measure of disease outcome in metastatie hormone refractory prostate cancer. J Clin Oncol 11:607–615, 1993.

    PubMed  CAS  Google Scholar 

  110. Sridhara R, Eisenberger M, Sinibaldi VJ, et al: Evaluation of prostate specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944–2953. 1995.

    PubMed  CAS  Google Scholar 

  111. Hussain M: The biology ol metastatie prostate cancer. In: Questions and uncertainties about prostate cancer. (Ed. Peeling WB). Blackwell Sciences, pp67-77, 1996b.

  112. Hussain M: Future directions in prostate cancer treatment: An oncologist’s perspective. The prostate. In press. 1996a.

  113. Mendoza E.Belldegrun A, Landaw E et al: Suramin efficacy and toxicity in hormone refractory metastatie prostate cancer. Proc ASCO 13:254, 1994.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Radiation Oncology, Detroit Medical Center, 48201, Detroit, Michigan, USA

    Kenneth V Honn, Amer Aref, Jeffrey D Forman, Xiang Gao, Arthur T Porter & Dean G Tang

  2. Departments of Pathology, Detroit Medical Center, 48201, Detroit, Michigan, USA

    Kenneth V Honn, Yong Q Chen, John D rissman, David Grignon & Wael Sakr

  3. Departments of Urology, Detroit Medical Center, 48201, Detroit, Michigan, USA

    Michael L Cher, J. Edson Pontes, Isaac Powell & David P Wood

  4. Departments of Medicine, Detroit Medical Center, 48201, Detroit, Michigan, USA

    Maha Hussain & Bruce Redman

  5. Family Medicine of Wayne State University, Detroit Medical Center, 48201, Detroit, Michigan, USA

    Richard Severson

  6. Barbara Ann Karmanos Cancer Institute, Detroit Medical Center, 48201, Detroit, Michigan, USA

    Kenneth V Honn, Amer Aref, Yong Q Chen, Michael L Cher, John D rissman, Jeffrey D Forman, Xiang Gao, David Grignon, Maha Hussain, Arthur T Porter, J. Edson Pontes, Isaac Powell, Bruce Redman, Wael Sakr, Richard Severson, Dean G Tang & David P Wood

Authors
  1. Kenneth V Honn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amer Aref
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong Q Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael L Cher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John D rissman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeffrey D Forman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiang Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David Grignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maha Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Arthur T Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. Edson Pontes
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Isaac Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Bruce Redman
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Wael Sakr
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Richard Severson
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Dean G Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. David P Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Part I and II have been published in previous issues of POR (Vol 2. 98-109. & 191-213.1996)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Honn, K.V., Aref, A., Chen, Y.Q. et al. Prostate cancer old problems and new approaches. Pathol. Oncol. Res. 2, 276–292 (1996). https://doi.org/10.1007/BF02904824

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02904824

Key words

Search

Navigation